Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers (PACIFIC BRAZIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04230408
Recruitment Status : Recruiting
First Posted : January 18, 2020
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Latin American Cooperative Oncology Group

Brief Summary:
This is a phase II study that will assess if Durvalumab (MEDI4736) used as induction chemo-immunotherapy followed by concurrent chemo-immuno-radiotherapy and consolidation immunotherapy may improve oncologic outcomes compared with standard of care chemoradiation followed by durvalumab (as in the PACIFIC trial) with a reasonable safety profile.

Condition or disease Intervention/treatment Phase
Lung Neoplasms Drug: Durvalumab Phase 2

Detailed Description:

Prospective, non-randomized, open label, single arm, multi-institutional, phase 2 study, including patients with stage III non-small cell lung cancer able to receive concurrent chemoradiation. Eligible patients will then receive treatment as follows:

Induction chemo-immunotherapy Two 21-day cycles of carboplatin, paclitaxel and durvalumab will be given BEFORE concurrent chemo-immuno-radiotherapy.

Thereafter, patients without progressive disease (or patients with disease progression that is still locally advanced and can be safely encompassed within tolerable radiation fields) will receive concurrent chemo-immuno-radiotherapy, as follows:

Concurrent chemo-immuno-radiotherapy Concurrent carboplatin, paclitaxel, and durvalumab with radiation therapy, initiated preferably 3-5 weeks after the last dose of induction chemo-immunotherapy.

Thereafter, patients without progressive disease will receive consolidation immunotherapy, as follows:

Consolidation immunotherapy Twelve 28-day cycles of durvalumab will be given, initiated preferably within one week following concurrent chemo-immuno-radiotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective single-arm study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)
Actual Study Start Date : January 29, 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: DURVALUMAB (MEDI4736) + carboplatin-paclitaxel

Induction chemo-immunotherapy phase:

Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.

Concurrent chemo-immuno-radiotherapy phase:

Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.

Concurrent chemo-immuno-radiotherapy:

Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses

Drug: Durvalumab
Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
Other Names:
  • Carboplatin
  • Paclitaxel




Primary Outcome Measures :
  1. 12 months Progression-Free Survival [ Time Frame: Tumor scans will be performed at baseline, after the induction and concomitant phases and 3, 6, 9, and 12 months after the last dose of radiation therapy. ]
    Proportion of patients who are alive and progression-free 12 months after cycle 1, day 1 of induction treatment, estimated by the Kaplan-Maier method and using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: OS will be evaluated until month 24 after C1D1. ]
    Time from cycle 1, day 1 of induction treatment until death due to any cause.

  2. Overall response rate to induction treatment [ Time Frame: Tumor scans will be performed at baseline, after the induction and concomitant phases and 3, 6, 9, and 12 months after the last dose of radiation therapy. ]
    The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1.

  3. Patterns of Failure [ Time Frame: Tumor scans will be performed at baseline, after the induction and concomitant phases and 3, 6, 9, and 12 months after the last dose of radiation therapy. ]
    Rate of disease failure in local, regional and distant sites



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  1. Histologically or cytologically confirmed non-small cell lung cancer.
  2. Stage III according to the American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition.
  3. No prior systemic therapy, radiation therapy, or surgery for the current cancer.
  4. Age ≥ 18 years at time of study entry
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  6. Body weight >30kg
  7. Pre- or post-bronchodilator forced expiratory volume 1 ≥ 1.2 litres/second or ≥ 50% of predicted value
  8. Adequate normal organ and marrow function

EXCLUSION CRITERIA

  1. Patients whose radiation treatment is likely to encompass a volume of whole lung receiving ≥ 20 Gy in total of more than 35% of lung volume.
  2. Patients whose radiation treatment is likely to deliver a cardiac dose V50 > 25%
  3. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
  4. Participation in another clinical study with an investigational product with anti-neoplastic activity during the last 3 weeks prior to treatment initiation
  5. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  6. History of allogenic organ transplantation.
  7. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
  8. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
  9. Prior randomisation or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.
  10. Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4 antibodies
  11. Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product.
  12. Prior radiation therapy to the region of the study cancer that would result in overlap of radiation therapy fields.
  13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of the investigational product.
  14. Active or prior documented autoimmune or inflammatory disorders
  15. Uncontrolled intercurrent illness
  16. History of another primary malignancy
  17. Known active infection including tuberculosis , hepatitis B, hepatitis C, or human immunodeficiency virus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04230408


Contacts
Layout table for location contacts
Contact: Gustavo Werutsky +55 51 3384 5334 gustavo.werutsky@lacogcancerresearch.org
Contact: Laura Voelcker +55 51 3384 5334 laura.voelcker@lacogcancerresearch.org

Locations
Layout table for location information
Brazil
Liga Norte Riograndense Contra o Câncer Not yet recruiting
Natal, Rio Grande Do Norte, Brazil, 59075-740
Contact: Danielli Matias, MD    55 84 4009 5595    danielli.matias@liga.org.br   
CPO Recruiting
Porto Alegre, Rio Grande Do Sul, Brazil
Contact: Gustavo Werutsky         
Principal Investigator: Gustavo Werutsky         
INCA Recruiting
Rio De Janeiro, RJ, Brazil
Contact: Luiz Henrique de Lima Araújo         
Instituto D'OR Not yet recruiting
Rio De Janeiro, RJ, Brazil
Contact: Clarissa Baldotto         
Principal Investigator: Clarissa Baldotto, MD         
COI Américas Not yet recruiting
Rio De Janeiro, Brazil
Contact: Luiz Henrique de Lima Araujo         
Principal Investigator: Luiz Henrique de Lima Araujo         
Beneficiencia Portuguesa de São Paulo/Hospital São José Recruiting
São Paulo, Brazil
Contact: William William         
Principal Investigator: William William, MD         
ICESP Not yet recruiting
São Paulo, Brazil
Contact: Gilberto Castro, MD         
Principal Investigator: Gilberto Castro, MD         
Sponsors and Collaborators
Latin American Cooperative Oncology Group
Layout table for additonal information
Responsible Party: Latin American Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT04230408    
Other Study ID Numbers: LACOG 2218
First Posted: January 18, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Latin American Cooperative Oncology Group:
Stage III Non-Small Cell Lung Cancer
Unresectable Non-Small Cell Lung Cancer
Durvalumab
MEDI4736
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Bronchial Neoplasms
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Paclitaxel
Carboplatin
Durvalumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological